Skip to main content

HubXchange

HubXChange logo

News Xchange

Page Banner 1

ADC Landscape in Flux: Layoffs, Setbacks, Legal Battles, and New Clinical Advances

The antibody-drug conjugate (ADC) development arena is experiencing a tumultuous phase marked by strategic pivots, trial disappointments, high-stakes legal clashes, and encouraging scientific wins. Recent events underscore the growing competitiveness – and complexity – of the ADC landscape, as companies recalibrate their approaches amid intense pressure to deliver results. In the past weeks, BioAtla, Inc. announced a major workforce reduction and refocused pipeline, MacroGenics, Inc. scrapped a once-promising B7-H3-targeting ADC after underwhelming data, AbbVie took Genmab to court over alleged theft of ADC trade secrets in a billion-dollar deal, and AstraZeneca reported exciting clinical progress with a B7-H4-targeted ADC moving toward Phase 3. Each of these developments is rippling across the ADC ecosystem – influencing funding, partnerships, legal risk, and the scientific rigor demanded in this fast-evolving field.

 

BioAtla Restructures and Pivots to Partnerships in Cost-Cutting Move

San Diego-based BioAtla is paring down its internal ADC efforts and seeking external partners, as it executes a significant restructuring. In an SEC filing and earnings update at the end of March, BioAtla revealed a workforce reduction of over 30% as part of a “resource realignment” designed to extend its cash runway beyond key clinical readouts in the first half of 2026​ biospace.com nasdaq.com. The company estimates roughly $0.6 million in one-time costs for the layoffs, mostly to be incurred in Q2 2025​ nasdaq.com. A BioAtla spokesperson framed the shift as transitioning “from building out our platform to accelerating the development of our pipeline,” necessitating a redesigned team structure biospace.com. In practical terms, BioAtla is trimming early-stage exploratory work to concentrate on advancing its lead programs and forging partnerships to share the burden on others.

In its latest update, BioAtla’s leadership emphasized prioritizing the most promising candidates in its conditionally active biologic (CAB) ADC platform. The company will focus internal resources on a handful of key programs – notably BA3182, a conditionally active EpCAMxCD3 T-cell engager in Phase 1, and mecbotamab vedotin (BA3011), a CAB-AXL-ADC in Phase 2 for non-small cell lung cancer​ biospace.com. Early data from these programs have shown encouraging signs (e.g. tumor reductions and prolonged disease control in heavily pretreated patients), reinforcing management’s conviction to invest in them. “We continue to advance multiple discussions with potential collaborators on our Phase 2 assets… [and] restructured the organization to further reduce costs, extend runway and prioritize new patient recruitment to programs that we believe can provide transformative results for our patients and shareholders alike,” said BioAtla CEO Jay Short in a statement​ nasdaq.com. In line with this strategy, other pipeline assets will be advanced via partnerships rather than internally. For example, BioAtla’s Phase 2 ozuriftamab vedotin (CAB-ROR2-ADC for head and neck cancer) and its CAB-CTLA-4 antibody program are now explicitly slated for development through corporate collaborators​ nasdaq.com nasdaq.com. By trimming its headcount and out-licensing some programs, BioAtla aims to conserve cash while still enabling its novel ADC candidates to progress in the clinic. This belt-tightening reflects the harsh reality for small and mid-size ADC developers: with limited resources and a competitive field, partnering can be essential to bring complex ADC therapies to fruition.

 

MacroGenics Scraps B7-H3 ADC After Disappointing Phase 2 Trial

Rockville, Maryland-based MacroGenics became the latest company to pull the plug on a late-stage ADC program in the face of mediocre efficacy data. The biotech announced it is discontinuing development of vobramitamab duocarmazine (also known as “vobra duo”), an ADC targeting B7-H3, after the drug flopped in a Phase 2 clinical trial for metastatic castration-resistant prostate cancer​ clinicaltrialsarena.com. The Phase 2 TAMARACK study enrolled nearly 200 mCRPC patients and tested two dose levels of vobra duo. Results showed median radiographic progression-free survival of only 9.5 and 10 months in the two dose cohorts – outcomes that failed to convincingly beat the standard of care or justify further investment​ clinicaltrialsarena.com. Following these underwhelming findings, MacroGenics’ leadership concluded the data “do not support additional financial investment” in vobra duo​ clinicaltrialsarena.com. The company’s stock tumbled ~10% after the news, reflecting investor disappointment in the once-high hopes for this ADC​ clinicaltrialsarena.com.

MacroGenics’ decision to cull the program was not taken lightly, as vobra duo was one of its more advanced assets. In fact, the company had already paused work on expanding vobra duo into other tumor types late last year, pending the prostate trial readout. With the Phase 2 outcome leaving much to be desired, MacroGenics has definitively abandoned vobra duo and is now exploring partnering opportunities to possibly hand off the program​ clinicaltrialsarena.com. “The results of the TAMARACK study… do not support additional financial investment by MacroGenics. We believe the B7-H3 target continues to have potential and are pleased with the progress being made with our alternate anti-B7-H3 ADC, MGC026,” said MacroGenics President Dr. Scott Koenig​ clinicaltrialsarena.com. This statement underscores that the company isn’t giving up on B7-H3 as a cancer target – rather, it is pivoting to a next-generation ADC approach. MGC026, currently in Phase 1, also targets B7-H3 but utilizes a different warhead (a topoisomerase-I inhibitor payload) and the same antibody binder, aiming to improve on vobra duo’s efficacy​ clinicaltrialsarena.com clinicaltrialsarena.com. The contrast between the two B7-H3 ADCs – one shelved, one rising – highlights the iterative nature of ADC development, where initial failures can seed new innovations. MacroGenics’ course-correction also serves as a cautionary tale: even a biologically compelling target like B7-H3 must deliver clear clinical benefit (with manageable safety) to survive in the competitive ADC pipeline. The willingness to terminate an underperforming program reflects increasing financial discipline and scientific rigor in the field, as companies funnel resources to only their most promising ADC candidates.

 

AbbVie and Genmab in Legal Showdown Over Alleged ADC Trade Secret Theft

In a dramatic turn, a high-profile legal battle has erupted that underscores the fierce competition for ADC technology. Pharma giant AbbVie has sued its longtime collaborator Genmab – along with Genmab’s recently acquired subsidiary ProfoundBio – alleging misappropriation of trade secrets related to a novel ADC linker platform​ life-sciences-usa.com , life-sciences-usa.com. The complaint, filed in U.S. federal court in Seattle, claims that former AbbVie scientists illicitly shared proprietary know-how with ProfoundBio, enabling the biotech to develop cutting-edge hydrophilic linkers for its ADCs​ pharmaphorum.com. Specifically, AbbVie accuses the defendants of stealing technology involving the use of disaccharides to improve the hydrophilicity of ADC drug-linkers – a design that can enhance drug delivery properties​ life-sciences-usa.com. That proprietary linker design is at the heart of ProfoundBio’s ADC platform, including its lead compound rinatabart sesutecan (Rina-S™), a folate receptor-alpha (FRα)-targeting ADC now in Phase 3 trials​ life-sciences-usa.com, life-sciences-usa.com. AbbVie alleges this know-how gave ProfoundBio an unfair boost, turning a struggling pipeline into a success and ultimately attracting Genmab’s acquisition of the company in 2024 for $1.8 billion​ pharmaphorum.com. In the court filing, AbbVie even suggests ProfoundBio “cashed out” by touting what were essentially AbbVie’s trade secrets as its own inventions – a strategy that prompted Genmab’s big-ticket buyout of the firm​ pharmaphorum.com.

Genmab has categorically denied the accusations and vows to fight the lawsuit vigorously​ life-sciences-usa.com, pharmaphorum.com. The Danish biotech asserts that AbbVie has no actual patent infringement claim and points out that AbbVie itself never commercialized the disputed linker approach​ life-sciences-usa.com, pharmaphorum.com. Moreover, Genmab’s management noted that this is one of multiple recent cases where AbbVie has sued competitors over trade secrets tied to ex-employees, implying a broader defensive campaign by AbbVie as ADC technologies proliferate​ life-sciences-usa.com, pharmaphorum.com. Notably, the legal friction comes despite a long-standing partnership between AbbVie and Genmab in oncology: the two companies inked a $3.9 billion collaboration in 2020 and co-market the T-cell engager epcoritamab (Epkinly) for lymphoma pharmaphorum.com. That relationship now faces strain. A multibillion-dollar alliance “risks being soured by [this] lawsuit,” as one industry publication put it pharmaphorum.com, though Genmab insists the joint epcoritamab program will continue unaffected for now​ pharmaphorum.com. The stakes extend beyond this partnership – the case sends ripples through the ADC sector. Competing developers are watching closely, as the outcome could shape how aggressively companies protect their ADC innovations and recruit talent. Trade secrets – such as linker chemistries that improve drug-antibody ratio or tumor targeting – are becoming as strategically vital as formal patents in the ADC arms race. The AbbVie-Genmab clash is a stark reminder of the legal risks that emerge when big money, breakthrough science, and overlapping talent pools intersect. It highlights the need for robust diligence and IP safeguards in any deals involving prized ADC technology, and it underscores that even trusted partners may turn to courtroom battles to defend their piece of a very lucrative pie.

 

AstraZeneca’s B7-H4 ADC Shows Promise, Advancing to Phase 3 amid Heavyweight Investment

Counterbalancing the retrenchments and disputes elsewhere in the field, AstraZeneca is forging ahead with new ADC successes, exemplifying how big pharma’s deep resources are propelling next-generation ADCs into late-stage trials. AstraZeneca’s oncology R&D group recently presented impressive first-in-human results for its B7-H4-targeting ADC (known as AZD8205, or by the generic name puxitatug samrotecan). In a Phase 1/2a study dubbed BLUESTAR, AZD8205 demonstrated encouraging efficacy in advanced endometrial cancer, a setting with high unmet need. Among 52 evaluable patients whose tumors expressed B7-H4, the ADC achieved confirmed objective response rates of ~35% and ~38% at two dose levels tested​ onclive.com. Responses included multiple partial responses in patients who had already exhausted standard therapies (including chemotherapy and immunotherapy). The median progression-free survival in both dose cohorts was on the order of 7 months, an outcome that suggests meaningful disease control in this heavily pretreated population​onclive.com. Safety data were likewise favorable – most side effects were manageable (primarily gastrointestinal or hematologic), and no patients discontinued therapy due to adverse events​ onclive.com. Investigators viewed the results as sufficiently promising to warrant aggressive further development. AstraZeneca announced plans for a global Phase 3 trial of AZD8205 in B7-H4–positive endometrial cancer, pitting the ADC against standard chemotherapy​ onclive.com. This pivotal study is expected to initiate in the near term, aiming to confirm the efficacy signal and support regulatory approval if successful.

AstraZeneca’s push with the B7-H4 program underlines its continued confidence and investment in ADCs as a cornerstone of its oncology strategy. The company – already a leader in the space through its collaboration with Daiichi Sankyo on ADCs like Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan – has been expanding its internal ADC pipeline, with AZD8205 being a notable homegrown asset. B7-H4 (also known as VTCN1) is an immune checkpoint protein overexpressed in various solid tumors (including endometrial and ovarian cancers) but with limited expression in normal tissues, making it an attractive ADC target​ annalsofoncology.org. AstraZeneca deployed a sophisticated topoisomerase-1 inhibitor payload and a proprietary hydrophilic linker in AZD8205, reflecting the state-of-the-art design elements companies are now leveraging to improve ADC performance. By swiftly moving AZD8205 into Phase 3 on the strength of Phase 1/2 data, AstraZeneca is effectively raising the competitive bar – smaller companies will need similarly robust early data (or willing big partners) to keep pace. Industry experts note that big pharmas like AstraZeneca can marshal the capital, clinical trial networks, and regulatory clout to accelerate development of promising ADCs, potentially seizing the advantage in emerging targets like B7-H4. If AZD8205’s Phase 3 confirms its initial results, it could position AstraZeneca as the first to bring a B7-H4-directed ADC to market, opening a new front in the ADC therapy class. Beyond the specific drug, this momentum reinforces the optimism around ADCs’ clinical potential, even as other efforts have stumbled. It also exemplifies the scientific rigor required to succeed – AstraZeneca’s program benefitted from careful target selection and engineering to achieve a tolerable safety profile, aspects that only come from substantial upfront investment in ADC research.

 

A Complex and Competitive ADC Ecosystem

Taken together, these developments paint a picture of an ADC ecosystem that is dynamic, fiercely competitive, and strategically complex. In the span of a week, we’ve seen a small biotech retrench and seek alliances to survive, a mid-size developer pivot after a clinical setback, two industry giants locking horns over the very building blocks of ADC design, and a major pharmaceutical company charging forward with breakthrough data. The impacts are far-reaching. Funding and investor sentiment continue to flow toward ADC programs with strong data, but there is little patience for mediocrity – as evidenced by MacroGenics’ trial halt and BioAtla’s pipeline pruning. Collaboration is a double-edged sword: companies like BioAtla are courting partnerships as lifelines, yet AbbVie vs. Genmab shows how collaborations can devolve into acrimony if intellectual property ownership is in doubt. The legal risks in the ADC realm are escalating in step with its high valuations, prompting firms to more closely guard proprietary methods (or vet acquisition targets more thoroughly). At the same time, scientific progress marches on, with players like AstraZeneca demonstrating that rigorous R&D can yield ADC therapies that inch closer to fulfilling the modality’s promise for patients.

Observers of the sector point out that the current wave of ADC news is a sign of a maturing field entering a pivotal phase. The surge of investment and pipeline activity in recent years – including multi-billion-dollar deals and acquisitions – is now meeting the realities of development: some programs will falter, consolidation is likely, and only the most compelling new therapies will reach the finish line. “The excitement around ADCs remains high, but so is the bar for success,” remarked one industry analyst. In this climate, senior scientists and R&D strategists are increasingly focused on differentiation – whether through novel targets, better linkers and payloads, or smarter trial design – to ensure their ADC candidates stand out in a crowded arena. Business development executives, for their part, are navigating a minefield of opportunities and risks: lucrative partnerships beckon, but picking the right ally (and protecting one’s technology) is more critical than ever. For all stakeholders, the recent events serve as a reminder that progress in the ADC space will come with twists and turns. The endgame, however, is shared by all – to harness the unique power of antibody-drug conjugates and ultimately deliver transformative cancer treatments. As the ADC race heats up, adaptability, vigilance, and innovation will be key to determining who thrives in this complex ecosystem and who falls behind.

 

 

 

Sources:

View all News Xchange
Loading
Search